Sanofi: more investments for cemiplimab antibody
(CercleFinance.com) - Sanofi and Regeneron Pharmaceuticals Inc.
announced on Monday their intensification and increased investment in the clinical development of the cemiplimab anti-PD-1 (programmed cell death receptor-1) antibody in oncology, as well as the dupilumab antibody in the treatment of type 2 allergic diseases.
Both these innovative therapies will potentially benefit many different patient populations and these strategic investments will enable both companies to assess cemiplimab and dupilumab as part of large-scale clinical development programs.
By virtue of this decision, Sanofi and Regeneron will increase their investments in the clinical development of cemiplimab to 1.64 billion dollars, which is about 1 billion dollars more than what was included in the initial 2015 agreement, which they will continue to finance equally.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
announced on Monday their intensification and increased investment in the clinical development of the cemiplimab anti-PD-1 (programmed cell death receptor-1) antibody in oncology, as well as the dupilumab antibody in the treatment of type 2 allergic diseases.
Both these innovative therapies will potentially benefit many different patient populations and these strategic investments will enable both companies to assess cemiplimab and dupilumab as part of large-scale clinical development programs.
By virtue of this decision, Sanofi and Regeneron will increase their investments in the clinical development of cemiplimab to 1.64 billion dollars, which is about 1 billion dollars more than what was included in the initial 2015 agreement, which they will continue to finance equally.
Copyright (c) 2018 CercleFinance.com. All rights reserved.